EIKN
Eikon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$10.96
+0.00%Institutional positioning
13F filings over the trailing two quarters
New 5Increased 0Reduced 1Sold out 51
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 969,431 | May 15, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 131,954 | May 8, 2026 |
| Vanguard Global Advisers, LLC | New Position | 13,747 | May 8, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 13,613 | May 8, 2026 |
| CITADEL ADVISORS LLC | Reduced | 13,023 | Sep 2, 2026 |
| JPMORGAN CHASE & CO | New Position | 1,300 | May 13, 2026 |
| Vanguard Global Advisers, LLC | Sold Out | 0 | May 8, 2026 |
| Quantbot Technologies LP | Sold Out | 0 | May 13, 2026 |
| SOROS CAPITAL MANAGEMENT LLC | Sold Out | 0 | May 15, 2026 |
| Capital World Investors | Sold Out | 0 | May 13, 2026 |
| Comprehensive Financial Management LLC | Sold Out | 0 | May 15, 2026 |
| Foresite Capital Management IV, LLC | Sold Out | 0 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Sold Out | 0 | May 15, 2026 |
| JANE STREET GROUP, LLC | Sold Out | 0 | May 12, 2026 |
| TD ASSET MANAGEMENT INC | Sold Out | 0 | May 11, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings